AUTHOR=Phan Phuc H. , Nguyen Dung T. , Dao Nam H. , Nguyen Ha T. T. , Vu An V. , Hoang Son T. , Nguyen Lam V. , Cao Tung V. , Tran Dien M. 

TITLE=Case Report: Successful Treatment of a Child With COVID-19 Reinfection-Induced Fulminant Myocarditis by Cytokine-Adsorbing oXiris® Hemofilter Continuous Veno-Venous Hemofiltration and Extracorporeal Membrane Oxygenation

JOURNAL=Frontiers in Pediatrics

VOLUME=Volume 10 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2022.946547

DOI=10.3389/fped.2022.946547

ISSN=2296-2360

ABSTRACT=Background: Indirect cardiomyocyte damage-related hyperinflammatory response is one of the key mechanisms in Covid-19-induced fulminant myocarditis. In addition to the clinical benefit of using cytokines absorption hemofiltration, the effectiveness of instituting VA-ECMO support for cardiac compromise has been reported. However, current literature enunciates a paucity of available data on the effectiveness of these novel modalities.
Case presentation: We reported a 9-year-old boy with recurrent COVID-19 infection causing fulminant myocarditis, who was treated successfully by using novel modalities of oXiris®  hemofilter continuous venovenous haemofiltration (CVVH) and veno-arterial extracorporeal membrane oxygenation (VA-ECMO).  The patient made a full recovery without any sequelae.
Conclusion: We conclude that the novel highly-absorptive hemofilter CVVH and VA-ECMO may be effective treatment modalities in managing SARS-CoV-2-induced fulminant myocarditis. Our report highlights the need for further well-designed investigations to confirm this extrapolation.